InMed Pharmaceuticals (INM)
(Real Time Quote from BATS)
$0.26 USD
0.00 (-1.14%)
Updated Jun 27, 2024 03:06 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INM 0.26 0.00(-1.14%)
Will INM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for INM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INM
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
INM: What are Zacks experts saying now?
Zacks Private Portfolio Services
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates
Other News for INM
InMed Pharmaceuticals to Showcase at Growth Conference
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024